Delayed Total Knee Replacement with Hylan G-F 20.

Area of Science:

• Orthopedics
• Rheumatology
• Biomaterials Science

Background:

• Osteoarthritis (OA) is a degenerative joint disease leading to significant pain and disability.
• Total knee replacement (TKR) is a common surgical intervention for end-stage OA.
• Hylan G-F 20, a hyaluronic acid derivative, is used for OA symptom management.

Purpose of the Study:

• To evaluate the long-term efficacy of Hylan G-F 20 in delaying TKR in patients with Grade IV OA.
• To assess the influence of Hylan G-F 20 on the time to TKR in two distinct patient cohorts.

Main Methods:

• Retrospective analysis of prospective data from 1997-2010.
• Inclusion of two cohorts: full cohort (1,863 knees) and original cohort (1,187 knees).
• Survival analysis to determine time to TKR after Hylan G-F 20 treatment.

Main Results:

• Approximately 25-28% of knees underwent TKR, with an average delay of 2.8-3.1 years post-injection.
• Survival analysis indicated TKR was delayed for over 7 years in 75% of patients.
• Age was a significant predictor of time to TKR; mild to moderate synovitis noted with repeat injections.

Conclusions:

• Hylan G-F 20 treatment continues to demonstrate a significant ability to delay the need for total knee replacement in patients with Grade IV osteoarthritis.
• The findings support the long-term utility of Hylan G-F 20 as a conservative management option for severe OA, extending the period before surgical intervention is required.